Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (Nasdaq: CSTL) is a diagnostics company focused on molecular tests that guide patient care in dermatologic and gastroenterological disease. The CSTL news feed highlights company announcements, clinical data, financial results and corporate updates that shape how investors and clinicians view its role in precision medicine.
Readers can follow news on Castle’s core test portfolio, including DecisionDx-Melanoma for cutaneous melanoma, TissueCypher Barrett’s Esophagus, DecisionDx-SCC for high-risk cutaneous squamous cell carcinoma, MyPath Melanoma and its suite of tests for uveal melanoma such as DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq. Coverage also includes updates on AdvanceAD-Tx, the company’s gene expression profile test designed to guide systemic treatment decisions in moderate-to-severe atopic dermatitis.
In addition to product and clinical evidence updates, CSTL news items feature quarterly and annual financial results, test volume trends for core revenue drivers, and guidance ranges reported in earnings releases. Regulatory and corporate governance developments, such as bylaw amendments disclosed in Form 8-K filings, as well as participation in healthcare and investor conferences, are also common topics.
Because Castle Biosciences emphasizes rigorous clinical validation, many news releases center on new studies, meta-analyses and expert consensus papers that evaluate the performance of its tests in real-world and prospective cohorts. These articles provide insight into how DecisionDx-Melanoma, TissueCypher and other assays are being integrated into clinical decision-making.
For investors, clinicians and researchers tracking CSTL, this news page offers a centralized view of earnings announcements, product launches, reimbursement developments, clinical data presentations and corporate events related to Castle Biosciences’ molecular diagnostics business.
Castle Biosciences (Nasdaq: CSTL) announced a study showing increasing use of its DecisionDx®-Melanoma test among dermatologists for managing melanoma patients. The study featured responses from 589 U.S. dermatologists, revealing that 45% ordered the test in the last year, with 82% likely to do so moving forward. DecisionDx-Melanoma significantly influences treatment decisions, particularly for early-stage melanomas, with a Class 1A result showing a 96.8% 5-year recurrence-free survival rate. Dermatologists reported benefits for patients, such as reduced anxiety and improved treatment personalization.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced its financial results for 2020, achieving revenues of $62.6 million, up 21% from 2019. The company expanded its product offerings to three skin cancer tests, increasing its U.S. total addressable market to $2 billion. The integrated AI-based DecisionDx-Melanoma test was launched, promising improved risk predictions. However, operating cash flow dropped to $9.9 million, and fourth-quarter revenue slightly declined to $17.3 million. With $410 million in cash, the company remains positioned for growth, predicting an additional $3.6 billion market opportunity.
Castle Biosciences (Nasdaq: CSTL) announced enhancements to its DecisionDx®-Melanoma test, now featuring an Integrated Test Result (ITR) that provides improved risk predictions for melanoma patients. This update is driven by an AI-based algorithm (i31-GEP) validated through testing of 1,674 patients. The updated test not only predicts sentinel lymph node positivity but also offers 5-year survival outcomes. An app for dermatology clinicians will be launched later in 2021, utilizing the ITR to enhance patient management decisions. DecisionDx-Melanoma has been ordered over 68,920 times to date.
Castle Biosciences, Inc. (Nasdaq: CSTL) will announce its fourth-quarter and full-year financial results for 2020 after the market closes on March 8, 2021. A conference call and webcast will follow at 4:30 p.m. Eastern time to discuss these results and a corporate update. Interested parties can access the live webcast through the company’s Investor Relations page or by phone. Castle Biosciences focuses on providing personalized genomic information for skin cancer treatment decisions, offering tests for various melanoma types and other dermatologic diseases.
Castle Biosciences (Nasdaq: CSTL) announced that CEO Derek Maetzold will present at two investor conferences. The first is the BTIG Virtual MedTech Conference on Feb. 17, 2021, at 10:30 a.m. ET, followed by the 10th Annual SVB Leerink Global Healthcare Conference on Feb. 24, 2021, at 10:00 a.m. ET. Live webcasts of the presentations will be available on Castle's website, with replays accessible for two weeks afterward. Castle focuses on providing personalized genomic information to enhance treatment decisions for skin cancer.
Castle Biosciences (Nasdaq: CSTL) announced the presentation of virtual posters at the 19th Annual South Beach Symposium, highlighting its gene expression profile tests for skin cancer. Key studies include DecisionDx-Melanoma, which predicts melanoma metastasis risk, revealing that 75% of patients with T1b tumors could avoid sentinel lymph node biopsy, potentially saving $120 million in healthcare costs. DecisionDx DiffDx-Melanoma showed high diagnostic accuracy (99.1% sensitivity) and improved clinician confidence. DecisionDx-SCC aids in predicting metastasis risk in high-risk cutaneous SCC patients, improving management decisions.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced poster presentations featuring data on its skin cancer gene expression profile tests at the 18th Annual Winter Clinical Dermatology Conference from Jan. 15 – 24, 2021. The tests include DecisionDx®-Melanoma, which predicts melanoma metastasis risk, and DecisionDx® DiffDx™-Melanoma, designed for classifying difficult lesions. Key findings reveal DecisionDx-Melanoma significantly predicts sentinel lymph node positivity, while DecisionDx DiffDx-Melanoma boasts 98% sensitivity and 100% specificity in head and neck lesions.
Castle Biosciences (Nasdaq: CSTL) released preliminary performance results for Q4 and full-year 2020. Despite COVID-19 challenges, the company reported growth in DecisionDx®-Melanoma test reports, delivering 4,246 in Q4 and 16,232 for the year. They expanded their skin cancer product suite and launched the DecisionDx DiffDx-Melanoma test. The total addressable market for its tests is now estimated at $2 billion. Key financial highlights include a public offering that raised $266.8 million, boosting cash reserves to approximately $410 million by year-end.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that Derek Maetzold, CEO, will present a company overview at the 23rd Annual Needham Virtual Growth Conference on January 15, 2021, at 11:30 a.m. Eastern time. A live audio webcast of the presentation will be accessible on Castle Biosciences’ website, with a replay available for two weeks post-event. The company specializes in providing personalized genomic information to enhance cancer treatment decisions, offering tests for various skin cancers including melanoma and squamous cell carcinoma.
Castle Biosciences (Nasdaq: CSTL) has fully prepaid its term loan facility, improving its financial standing. The prepayment of approximately $21.6 million, which includes principal and interest, signifies a strategic move post its successful equity financing. This action terminates all obligations under the loan agreement, enhancing cash savings and enabling further development of its product pipeline. The company focuses on dermatologic cancer diagnostics and aims to leverage its strengthened financial position to support and grow its marketed products in 2021.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
